CMBI Expects Hengrui Pharma's (01276) IPO to Attract More Global Capital into HK Healthcare Sector

Intelligent Finance APP learned that China Merchants Securities International released a research report stating that they visited more than 40 clients in Shanghai, Beijing, Hong Kong, and Shenzhen over the past two weeks. The overall market sentiment towards the Hong Kong-listed healthcare sector is more optimistic compared to 2024. The firm expects that the Hengrui Pharma (01276) Hong Kong IPO will attract more global capital inflows into Hong Kong's medical sector. Currently, there remains a divergence among international investment institutions regarding allocation within this industry.

CMB International continues to be optimistic about the Hong Kong stock medical sector, with top picks: Hansoh Pharma (03692, Outperform), Innovent Bio (01801, Outperform), IFLY TEK (02506, Outperform), and CStone Pharmaceuticals (02616, Outperform). Also recommended for attention are CSPC (01093, Outperform) and Kang Nuoya Biomedical Technology (02162, Not Rated).